Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOLAMBA in Ragweed-Allergic Rhinitis Adults
NCT00387738Phase 2Terminated
- Sponsor
- Dynavax Technologies
- Start
- Apr 2006
- Primary completion
- May 2007
- Modality
- Antisense DNA, Prophylactic Vaccines, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate in ragweed allergy (3 arms), sponsored by Dynavax Technologies. Primary endpoint: Total Nasal Symptom Score at 2 years. Started Apr 2006; status: terminated.
02
Drugs
amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate
03
Conditions
ragweed allergy
Beyond the preview
Go deeper on NCT00387738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00387738.